ICICI to fund Dr Reddy’s R&D move
Pharma major Dr Reddy’s Laboratories (DRL) has entered into $56 million agreement with ICICI Venture Funds Management Company for the development and commercialisation of abbreviated new drug application to be filed in 2004-05 and 2005-06.

USFDA approves Bristol-Myer’s entecavir for chronic hepatitis B
Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved entecavir – indicated for the treatment of chronic hepatitis B infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease, according to a press release.